[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562613":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":34,"locations":43,"responsibleParty":75,"collaborators":77,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":82,"sex":88,"minAge":89,"maxAge":10,"enrollmentInfo":90,"targetDuration":10,"studyType":93,"phases":10,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":61,"whyStopped":10,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Fundacion Clinic per a la Recerca Biomédica","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Melanoma (non-metastatic)",null,"Patients of either sex over 18 years old with histopathological confirmed melanoma in a non metastatic stage (I to IIb stages according to AJCC classification)",[13,14,15],"Device: Breath analyzer","Device: Skin patch","Genetic: Liquid biopsy",{"label":17,"type":10,"description":18,"interventionNames":10},"Melanoma (metastatic)","Patients of either sex over 18 years old with histopathological confirmed melanoma in a metastatic stage (IIIa to IV stages according to AJCC classification)",[20,25,29],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DEVICE","Breath analyzer","The study subject will be advised to sit quietly for minimum 10 minutes prior the sampling to avoid temporal changes in levels of volatile organic compunds (VOCs) related to body movement or try to avoid abrupt changes in body posture. Then, he\u002Fshe will be asked to blow in the breath analyzer in order to obtain the exhaled VOCs profile.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Skin patch","A skin patch will be placed in the anterior part of the patient's arm for the obtention of the skin VOCs profile (estimated sampling time of around 1 h). These profiles will be recorded with a dedicated software and analyzed using standard statistical methods.",[9],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"GENETIC","Liquid biopsy","Circulating free tumor DNA (cfDNA) will be extracted from patient's blood and analyzed to detect mutations in BRAF and other prognostic genes.",[9],[35,40],{"name":36,"role":37,"phone":38,"phoneExt":10,"email":39},"Susana Puig Sardà, PhD, MD","CONTACT","+34932275400","spuig@clinic.cat",{"name":41,"role":37,"phone":10,"phoneExt":10,"email":42},"Adrián López Canosa, PhD","lopez64@recerca.clinic.cat",[44,59,69],{"facility":45,"status":46,"city":47,"state":10,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Hospital Clínic de Barcelona (Dermatology service)","NOT_YET_RECRUITING","Barcelona","08036","Spain","ES",{"type":52,"coordinates":53},"Point",[54,55],2.15899,41.38879,{"lat":55,"lon":54},[58],{"name":36,"role":37,"phone":10,"phoneExt":10,"email":39},{"facility":60,"status":61,"city":47,"state":10,"zip":10,"country":49,"countryCode":50,"cosmosGeoPoint":62,"geoPoint":64,"contacts":65},"Hospital Clínic Barcelona","RECRUITING",{"type":52,"coordinates":63},[54,55],{"lat":55,"lon":54},[66,68],{"name":67,"role":37,"phone":38,"phoneExt":10,"email":39},"Susana Puig Sardà, MD, PhD",{"name":41,"role":37,"phone":10,"phoneExt":10,"email":42},{"facility":60,"status":61,"city":47,"state":10,"zip":10,"country":49,"countryCode":50,"cosmosGeoPoint":70,"geoPoint":72,"contacts":73},{"type":52,"coordinates":71},[54,55],{"lat":55,"lon":54},[74],{"name":67,"role":37,"phone":38,"phoneExt":10,"email":39},{"type":76,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[78],{"name":79,"class":6},"Hospital Clinic of Barcelona","100562613","precision-medicine-for-lgcmn-and-melanoma-2-100562613",false,"NCT06605443","Precision Medicine for L\u002FGCMN and Melanoma 2","Precision Medicine for L\u002FGCMN and Melanoma 1 (Precis-mel 2)","Precis-mel 2","Inclusion Criteria:\n\n* Be over 18 years old\n* Have a histopathological confirmed melanoma diagnosis (stage II, III or IV AJCC)\n\nExclusion Criteria:\n\n* Not signing the informed consent form\n* Present other cancers or chronic diseases (such as diabetes, asthma, etc.), which may affect the volatile organic compound profiles","ALL","18 Years",{"count":91,"type":92},100,"ESTIMATED","OBSERVATIONAL","The primary objective is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for the early identification of metastases. The secondary objective is to evaluate the usability of these technologies in the follow up of high-risk melanoma patients.",[96,97,98],"Melanoma (Skin Cancer)","Nevi and Melanomas","Congenital Melanocytic Nevus",[100,22,26,101,102,31,103,104],"Volatilomics","Melanoma","L\u002FGCMN","cfDNA","Non-invasive diagnostics","2025-02-25",{"date":107,"type":108},"2025-02-27","ACTUAL",{"date":110,"type":108},"2025-01-01",{"date":112,"type":92},"2026-12-01",{"name":5,"class":6},3]